central retinal vein occlusion
Conditions
Interventions
Intravitreal administration of Ranibizmab(Lucentis)
Sponsors
Nagasaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with macular edema due to central retinal vein occlusion. 2.Central retinal thickness-=>250µm 3.Point visual acuity less than 0.9 4.Age of patients 20years of age or older at the time of acquisition agreement. 5.After receiving a sufficient explanation upon participation in this study,on a full understanding,patients who obtained the document voluntary consent of the patient himself
Exclusion criteria
Exclusion criteria: 1.Patients who underwent the pan-retinal photocoagulation within 3 months. 2.Patients who underwent photocoagulation treatment for macular edema within 3 months. 3.Patients treated with steroids to intraocular within 3 months. 4.Patients who underwent anti-VEGF injection for macular edema within 3 months. 3.Patients treated with steroids to intraocular within 3 months. 5.The patients with a history of hypersensitivity to the study drug. 6.Patients who developed heart and cerebrovascular disease severe within 6 months. 7.Patients attending physician was deemed inappropriate as a subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The improvement rate of best corrected visual acuity at three months after the Ranibizmab injection. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-3.The changes of best corrected visual acuity, central retinal thickness, foveal choroidal thickness by OCT, retinal and choroidal blood flow changes by LSFG at 1 and 3 months after the Ranibizmab injection. 4.Duration from Ranobizmab injection to recurrence. 5.Adverse event | — |
Countries
Japan
Contacts
Public ContactEIKO TSUIKI
Nagasaki University Hospital Ophthalmology
Outcome results
None listed